<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34506130</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>39</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Biochemistry</Title><ISOAbbreviation>Biochemistry</ISOAbbreviation></Journal><ArticleTitle>Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode.</ArticleTitle><Pagination><StartPage>2925</StartPage><EndPage>2931</EndPage><MedlinePgn>2925-2931</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.biochem.1c00414</ELocationID><Abstract><AbstractText>Rupintrivir targets the 3C cysteine proteases of the picornaviridae family, which includes rhinoviruses and enteroviruses that cause a range of human diseases. Despite being a pan-3C protease inhibitor, rupintrivir activity is extremely weak against the homologous 3C-like protease of SARS-CoV-2. In this study, the crystal structures of rupintrivir were determined bound to enterovirus 68 (EV68) 3C protease and the 3C-like main protease (M<sup>pro</sup>) from SARS-CoV-2. While the EV68 3C protease-rupintrivir structure was similar to previously determined complexes with other picornavirus 3C proteases, rupintrivir bound in a unique conformation to the active site of SARS-CoV-2 M<sup>pro</sup> splitting the catalytic cysteine and histidine residues. This bifurcation of the catalytic dyad may provide a novel approach for inhibiting cysteine proteases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lockbaum</LastName><ForeName>Gordon J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0003-2720-6984</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henes</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeong Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timm</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9750-3293</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalivaika</LastName><ForeName>Ellen A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-1621-3372</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurt Yilmaz</LastName><ForeName>Nese</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5036-676X</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiffer</LastName><ForeName>Celia A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-2270-6613</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 GM133893</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM135919</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI149716</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM118112</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biochemistry</MedlineTA><NlmUniqueID>0370623</NlmUniqueID><ISSNLinking>0006-2960</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>47E5O17Y3R</RegistryNumber><NameOfSubstance UI="D010649">Phenylalanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C000706209">3C-like proteinase, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>HG18B9YRS7</RegistryNumber><NameOfSubstance UI="D014633">Valine</NameOfSubstance></Chemical><Chemical><RegistryNumber>RGE5K1Q5QW</RegistryNumber><NameOfSubstance UI="C118874">rupintrivir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020134" MajorTopicYN="N">Catalytic Domain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="N">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="N">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006860" MajorTopicYN="N">Hydrogen Bonding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010649" MajorTopicYN="N">Phenylalanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055672" MajorTopicYN="N">Static Electricity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014633" MajorTopicYN="N">Valine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>10</Day><Hour>17</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34506130</ArticleId><ArticleId IdType="mid">NIHMS1922355</ArticleId><ArticleId IdType="pmc">PMC8457326</ArticleId><ArticleId IdType="doi">10.1021/acs.biochem.1c00414</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Woolhouse M; Scott F; Hudson Z; Howey R; Chase-Topping M, Human viruses: discovery and emergence. Philos Trans R Soc LondB Biol Sci 2012, 367 (1604), 2864&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3427559</ArticleId><ArticleId IdType="pubmed">22966141</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SW; Pons-Salort M; Messacar K; Cook C; Meyers L; Farrar J; Grenfell BT, Epidemiological dynamics of enterovirus D68 in the United States and implications for acute flaccid myelitis. Sci TranslMed 2021, 13 (584).</Citation><ArticleIdList><ArticleId IdType="pubmed">33692131</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bos M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagace L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinas-Brunet M, An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426 (6963), 186&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">14578911</ArticleId></ArticleIdList></Reference><Reference><Citation>Surleraux DL; Tahri A; Verschueren WG; Pille GM; de Kock HA; Jonckers TH; Peeters A; De Meyer S; Azijn H; Pauwels R; de Bethune MP; King NM; Prabu-Jeyabalan M; Schiffer CA; Wigerinck PB, Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 2005, 48 (6), 1813&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15771427</ArticleId></ArticleIdList></Reference><Reference><Citation>El Bouzidi K; White E; Mbisa JL; Sabin CA; Phillips AN; Mackie N; Pozniak AL; Tostevin A; Pillay D; Dunn DT, HIV-1 drug resistance mutations emerging on darunavir therapy in Pi-naive and-experienced patients in the UK. Journal of Antimicrobial Chemotherapy 2016, 71 (12), 3487&#x2013;3494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181398</ArticleId><ArticleId IdType="pubmed">27856703</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de B&#xe9;thune M-P, TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrobial agents and chemotherapy 2005, 49 (6), 2314&#x2013;2321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1140553</ArticleId><ArticleId IdType="pubmed">15917527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengist HM; Dilnessa T; Jin T, Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front Chem 2021, 9, 622898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056153</ArticleId><ArticleId IdType="pubmed">33889562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghahremanpour MM; Tirado-Rives J; Deshmukh M; Ippolito JA; Zhang CH; Cabeza de Vaca I; Liosi ME; Anderson KS; Jorgensen WL, Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. ACS Med Chem Lett 2020, 11 (12), 2526&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605328</ArticleId><ArticleId IdType="pubmed">33324471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; Garcia-Sastre A; Krug RM; Montelione GT, Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Rep 2021, 35 (7), 109133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075848</ArticleId><ArticleId IdType="pubmed">33984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST, Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A 1999, 96 (20), 11000&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL; Maldonado F; Brothers MA; Weady PT; Zalman LS; Meador JW 3rd; Matthews DA; Patick AK, Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2005, 49 (2), 619&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG; Turner RB; Gwaltney JM; Chi-Burris K; Gersten M; Hsyu P; Patick AK; Smith GJ 3rd; Zalman LS, Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003, 47 (12), 3907&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsyu PH; Pithavala YK; Gersten M; Penning CA; Kerr BM, Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 2002, 46 (2), 392&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC127051</ArticleId><ArticleId IdType="pubmed">11796347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XN; Song ZG; Jiang T; Shi BS; Hu YW; Yuan ZH, Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection. World J Gastroenterol 2010, 16 (2), 201&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="pubmed">20066739</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L; Meijer A; Froeyen M; Zhang L; Thibaut HJ; Baggen J; George S; Vernachio J; van Kuppeveld FJ; Leyssen P; Hilgenfeld R; Neyts J; Delang L, Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother 2015, 59 (12), 7782&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4649165</ArticleId><ArticleId IdType="pubmed">26369972</ArticleId></ArticleIdList></Reference><Reference><Citation>Shie JJ; Fang JM; Kuo TH; Kuo CJ; Liang PH; Huang HJ; Wu YT; Jan JT; Cheng YS; Wong CH, Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters. BioorgMed Chem 2005, 13 (17), 5240&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7119063</ArticleId><ArticleId IdType="pubmed">15994085</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatansever EC; Yang K; Kratch KC; Drelich A; Cho CC; Mellott DM; Xu S; Tseng CK; Liu WR, Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19. bioRxiv 2020.</Citation></Reference><Reference><Citation>Wang J; Fan T; Yao X; Wu Z; Guo L; Lei X; Wang J; Wang M; Jin Q; Cui S, Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol 2011, 85 (19), 10021&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196404</ArticleId><ArticleId IdType="pubmed">21813612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S; Nitsche C, The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 2020, 30 (17), 127377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7331567</ArticleId><ArticleId IdType="pubmed">32738988</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrega-Ferrer M; Perez-Saavedra J; Herrera-Morande A; Coll M, 7P35 Structure of the SARS-CoV-2 3CL protease in complex with rupintrivir. July 21, 2021. ed.; RCSB PDB, 2021.</Citation></Reference><Reference><Citation>Verma N; Henderson JA; Shen J, Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors. J Am Chem Soc 2020, 142 (52), 21883&#x2013;21890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754784</ArticleId><ArticleId IdType="pubmed">33320670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum GJ; Reyes AC; Lee JM; Tilvawala R; Nalivaika EA; Ali A; Kurt Yilmaz N; Thompson PR; Schiffer CA, Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses 2021, 13 (2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7911568</ArticleId><ArticleId IdType="pubmed">33503819</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W, Xds. Acta Crystallogr D Biol Crystallogr 2010, 66 (Pt 2), 125&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>Otwinowski Z; Minor W, [20] Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997, 276, 307&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">27754618</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy AJ; Grosse-Kunstleve RW; Adams PD; Winn MD; Storoni LC; Read RJ, Phaser crystallographic software. JAppl Crystallogr 2007, 40 (Pt 4), 658&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J; George S; Kusov Y; Perbandt M; Anemuller S; Mesters JR; Norder H; Coutard B; Lacroix C; Leyssen P; Neyts J; Hilgenfeld R, 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol 2013, 87 (8), 4339&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P; Cowtan K, Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60 (Pt 12 Pt 1), 2126&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572765</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams PD; Afonine PV; Bunkoczi G; Chen VB; Davis IW; Echols N; Headd JJ; Hung LW; Kapral GJ; Grosse-Kunstleve RW; McCoy AJ; Moriarty NW; Oeffner R; Read RJ; Richardson DC; Richardson JS; Terwilliger TC; Zwart PH, PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010, 66 (Pt 2), 213&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriarty NW; Grosse-Kunstleve RW; Adams PD, electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr D Biol Crystallogr 2009, 65 (Pt 10), 1074&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748967</ArticleId><ArticleId IdType="pubmed">19770504</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunger AT, Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355 (6359), 472&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481394</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis IW; Leaver-Fay A; Chen VB; Block JN; Kapral GJ; Wang X; Murray LW; Arendall WB 3rd; Snoeyink J; Richardson JS; Richardson DC, MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007, 35 (Web Server issue), W375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933162</ArticleId><ArticleId IdType="pubmed">17452350</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman HM; Westbrook J; Feng Z; Gilliland G; Bhat TN; Weissig H; Shindyalov IN; Bourne PE, The Protein Data Bank. Nucleic Acids Res 2000, 28 (1), 235&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC102472</ArticleId><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman H; Henrick K; Nakamura H, Announcing the worldwide Protein Data Bank. Nat Struct Biol 2003, 10 (12), 980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14634627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>